Keyword: Otsuka Pharmaceutical
Avanir pays $116 million in Neudexta kickback suits; China unveils results for a procurement scheme; Aurobindo founder faces insider trading fine.
Avanir has reached a settlement with the feds over a yearslong marketing and kickbacks probe for Nuedexta.
Acadia Pharmaceuticals had to defend its Nuplazid safety last year, and now the drugmaker faces a DOJ probe into its marketing.
AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.
More than a year after CNN's exposé about Avanir's Neudexta marketing, the company is nearing a settlement with U.S. officials.
Antengene collects $120 million in series B; Otsuka inks new digital-pill pact; MabSpace merges with HJB.
Allegations in nearly a dozen kickbacks lawsuits against top pharma companies are unfounded, the government said.
As patients continue taking a more active role in healthcare, pharma's interest in digital therapeutics, already on a roll, will only accelerate.
The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
Cancer drugmakers cut prices by 56.7% for China; Celltrion's Rituxan biosim wins FDA panel support; Otsuka renews digital pill deal with Proteus.